Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.